Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Source:: Breaking News
Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Source:: Breaking News
Be First to Comment